ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow
NCT ID: NCT03654157
Last Updated: 2022-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1576 participants
OBSERVATIONAL
2018-03-25
2021-10-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Acute Coronary Syndrome (ACS) is the most prevalent manifestation of CVD and is associated with high mortality and morbidity. No other life-threatening disease is as prevalent or expensive to society3. In 2014 in Russian Federation 46 250 people died from acute myocardial infarction (MI) and 17 605 people died from recurrent MI4.
ACS is a clinical syndrome characterized by unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). The most common cause of ACS is reduced myocardial perfusion that results from coronary artery narrowing caused by the formation of partially or totally occlusive thrombi in response to rupture of atherosclerotic plaques on the vessel wall5-7.
In Russian Federation ACS management after ACS is provided in out-patient settings by doctors of different specialties (cardiologists and general practitioners (GPs)). However, the management of ACS in out-patient settings in some regions in Russian Federation is frequently suboptimal. Moscow city significantly differs from other parts of Russia from ACS management at hospital stage (up to 90% of PCI managed ST elevation myocardial infarction (MI) patients, no thrombolysis, short first medical contact to balloon time etc.) but it is unclear if management of post MI patients in Moscow out-patient settings is also optimal. In-hospital mortality in MI patients decreased last years but there is no data on clinical outcomes during 12 months after MI in Moscow.
This study will provide the epidemiological data about rates of major adverse cardiovascular and cerebrovascular events (MACCE) (MI, stroke, cardiovascular death) within 12 months after MI in real clinical practice in Moscow and describe DAPT at out-patient setting. The information received in this study will help to optimize management of Russian patients with ACS. The data will be used in discussion with payers
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
National, Multi-center, Prospective, and Retrospective Cohort Study.
NCT04520204
Study on Efficacy, Safety and Durability of the UniLine Prosthesis in the Treatment of Aortic and Mitral Valve Disease
NCT05895487
Telemonitoring of Patients With Acute Coronary Syndrome
NCT04862026
Mitral Valve in Hypertrophic Cardiomyopathy
NCT03877731
Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China
NCT07230756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients survivors who visited outpatient setting after discharge from hospital due to MI (STEMI or NSTEMI) within 1 month after discharge from hospital;
2. Obtained written informed consent for participation in this study.
3. Age of 18 year or older.
Exclusion Criteria
2. Unknown type of MI
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olga Pesheva
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 121 DZM
Tatyana Yurchak
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 52 DZM
Veronika Vovk
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 2 DZM
Dmitriy Privalov
Role: PRINCIPAL_INVESTIGATOR
GBUZ GKB # 51 DZM
Maria Klepikova
Role: PRINCIPAL_INVESTIGATOR
GBUZ GKB # 13 DZM
Olga Belkorey
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 218 DZM
Natalya Karabinskaya
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 19 DZM
Natalya Bosyakova
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 19 DZM
Marina Lepatova
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 107 DZM
Elena Dorofeeva
Role: PRINCIPAL_INVESTIGATOR
FGBU "Polyclinic # 1" Administrative Department of the President of the Russian Federation
Irina Shoshina
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 109 DZM
Darya Semenova
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 23 DZM
Elena Zherebetskaya
Role: PRINCIPAL_INVESTIGATOR
GBUZ KDC # 2 DZM
Marina Yarygina
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 175 DZM
Elena Lukinskaya
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 115 DZM
Irina Borovikova
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 209 DZM
Tatiana Sladkova
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 22 DZM
Elena Demyanova
Role: PRINCIPAL_INVESTIGATOR
GBUZ GP # 64 DZM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Research Site
Moscow, Moscow/Russia, Russia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000 Mar;83(3):361-6. doi: 10.1136/heart.83.3.361. No abstract available.
Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology; Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 Jul;28(13):1598-660. doi: 10.1093/eurheartj/ehm161. Epub 2007 Jun 14. No abstract available.
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000 Sep;36(3):970-1062. doi: 10.1016/s0735-1097(00)00889-5. No abstract available.
Vasilyeva EY, Plavunov NF, Kalinskaya AI, Sapina AI, Vvedensky GA, Lebedeva AY, Skrypnyk DV, Shpektor AV. [Treatment of Patients With Acute Myocardial Infarction With ST-Segment Elevation. Organization of the Myocardial Infarction Network in Moscow]. Kardiologiia. 2016 Dec;56(12):48-53. No abstract available. Russian.
Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015 May 14;36(19):1163-70. doi: 10.1093/eurheartj/ehu505. Epub 2015 Jan 13.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015 Jul 28;66(4):403-69. doi: 10.1016/j.jacc.2014.12.018. Epub 2014 Dec 29. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1843R00279
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.